Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy

Inclusion Criteria: * Histologically proven anal squamous cell carcinoma (SCC) (WHO 2004), including anal canal carcinoma (UICC 2002) and anal margin carcinoma (UICC 2002) * All stages except T1 N0 M0 after local excision (UICC 2002) * Age ≥ 18 years * ECOG Status 0-1 * Patients that have understand protocol and signed informed consent form * Sufficient bone marrow function: WBC ≥ 3,0 x 10\^9/l, Platelets ≥ 100 x 10\^9/l, Hemoglobin ≥ 10 g/dl * Sufficient liver function: Bilirubin \< 1,5 mg/dl, SGOT, SGPT, alkaline phosphatase, gGT less than 3 times upper limit of normal Exclusion Criteria: * Stage T1 N0 M0 after local excision (UICC 2002) * Uncontrolled, severe cardiac dysfunction (NYHA III/IV) * Pre-existing uncontrolled cardiac disease, signs of cardiac failure, or rhythm disturbances requiring therapy * Myocardial infarction within the past 12 months * Congestive heart failure * Complete bundle branch block * New York Heart Association (NYHA) class III or IV heart disease * Chronic inflammatory disease of the intestine * Active intractable or uncontrolled infection * Chronic diarrhea ( \> NCI CTC-Grad 1) * Acute thrombosis * Collagen vascular disease * Cardiac pacemaker * HIV-infection; Patients with hepatitis A or B virus infection, with HPV infection or Patients receiving immune suppressive treatment can be included * Devices that preclude deep regional hyperthermia (Endoprosthesis, stent in vascular system, acute thrombosis) * Any metal implants (with exception of non-clustered marker clips) * Conditions that preclude the application of fractionated pelvic radiotherapy * Conditions that preclude regular follow-up * Pregnant or breast feeding women * Prior pelvic radiotherapy * Prior chemotherapy * Drug addiction * On-treatment participation on other trials * Prior or concurrent malignancy or leucemia (≤ 5 years prior to enrolment in study) except anal cancer or non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1 if the patient is continuously disease-free * The presence of increased radiation sensitivity, for example ataxia teleangiectatica, or similar * Psychological, familial, sociological, or geographical condition that would preclude study compliance